Please login to the form below

Not currently logged in

Bristol-Myers Squibb and AstraZeneca to commercialise diabetes drug in Japan

Bristol-Myers Squibb and AstraZeneca have announced the expansion of their worldwide collaboration

Bristol-Myers Squibb and AstraZeneca have announced the expansion of their worldwide collaboration to include the development and commercialisation of their Type II diabetes drug, dapagliflozin in Japan.

The two companies entered into a global collaboration, which excluded Japan, in January 2007. They have now agreed to co-develop dapagliflozin in Japan where AstraZeneca will take operational and cost responsibility for all regulatory and development activities. The drug will be marketed jointly, with all expenses and profits (or losses) split equally. Bristol-Myers Squibb will manufacture dapagliflozin and book sales. The potential once-daily treatment for Type II diabetes is currently undergoing phase II clinical trials in Japan.

"Last year, the cost of treating and preventing Type II diabetes and its complications in Japan was more than $18.4bn, which is a significant cost to Japanese society," said Bruno Angelici, executive vice president, international sales and marketing organization, AstraZeneca.

"We have a long-standing presence in Japan, and our agreement with Bristol-Myers Squibb to bring a potentially important Type II diabetes treatment to market in the region will not only help reduce this cost burden, but also reduce the impact this disease has on the country's health."

Lamberto Andreotti, executive vice president and chief operating officer at Bristol-Myers Squibb said that the companies' shared vision for diabetes treatments means that a potential six million people in Japan with Type II diabetes could benefit from dapagliflozin.

17th December 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...